Supplementary Figure S4 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Year: 2024
Type: supplementary-materials
Abstract: Relationship of cfDNA concentration and circulating tumor DNA (ctDNA) with residual cancer burden (RCB) index. A. CfDNA (ng/mL, log10-transformed) and B. ctDNA concentrations (mean tumor molecules per mL of plasma, MTM/ml, log10-transformed) were measured in the plasma of patients with hormone receptor-positive HER2-negative (HR+HER2-) and triple-negative breast cancer (TNBC). The RCB index is a continuous measure of residual cancer in the breast and axillary lymph nodes after neoadjuvant chemotherapy, with an RCB index of zero equivalent to a pathologic complete response. The blue line represents the regression line, and the gray shading shows the 95% confidence interval. Pearson’s correlation test was used to calculate the correlation coefficient and the p-value. Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy before surgery (T3).
Authors: Mark Jesus M. Magbanua, Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Jane Perlmutter, Paula Pohlmann, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van 't Veer
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4399297871